<DOC>
	<DOC>NCT00958308</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Bio-K+ CL-1285 in the prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridum difficile-Associated Diarrhea (CDAD) in hospitalized patients exposed to nosocomial infection.</brief_summary>
	<brief_title>Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Antibiotic therapy for a minimum of 3 days and a maximum of 14 days Expected to remain hospitalized for a minimum of 5 days Patients who have received less than 36 hours of antibiotic therapy Negative pregnancy test at screening Obtained his/her informed consent after verbal and written information Patients having a telephone available (mobile, work, home) Patients having a fridge at home Pregnant or breastfeeding women Patients presenting with active diarrhea (3 or more liquid stools per 24 hour period). Patients with a history of daily consumption of probiotics, fermented milk and/or yogurt; Patients known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. Nonmedicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetal source), ascorbic acid, Colloidal silicon dioxide) Patients presenting with an active, noncontrolled intestinal disease such as Crohn's Disease or ulcerative colitis; A previous documented C. Difficile infection &lt; 3 months prior to study initiation ; Ostomized patients, parenteral nutrition users Patients with an immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, acquired immune deficiency syndrome (AIDS)) Ongoing or recent use of antibiotic therapy in the 30 days prior to the study product first administration. Patients with planned administration of antibiotics other than broad spectrum Penicillin, Cephalosporin or Clindamycin for the treatment of an infection; Patients with concomitant participation in another clinical trial; Patients who are not likely to comply with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Probiotic</keyword>
	<keyword>Antibiotic-Associated Diarrhea (AAD) Prevention</keyword>
	<keyword>Clostridium Difficile-Associated Diarrhea (CDAD)Prevention</keyword>
</DOC>